Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops targeted therapies for autoimmune diseases and cancer. Based in Cambridge, Massachusetts, the company focuses on creating treatments that inhibit key disease drivers or harness the immune system to eliminate diseased cells. Its clinical pipeline is highlighted by CLN-978, a CD19xCD3 bispecific T cell engager being evaluated for autoimmune conditions such as systemic lupus erythematosus and rheumatoid arthritis. In oncology, the company is advancing CLN-049 for acute myeloid leukemia and co-developing zipalertinib, a small molecule therapy for non-small cell lung cancer, alongside Taiho Pharmaceutical. Originally founded as Cullinan Oncology, the company rebranded and strategically expanded its focus to include immunology in 2024.
